Kei Ohnuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kei Ohnuma has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Ryo Hatano
Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan
19 shared publications - Chikao Morimoto
Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan
15 shared publications Nam H. Dang
Division of Hematology/Oncology, University of Florida, Gainesville, USA
15 shared publicationsChikao Morimoto
Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Japan
12 shared publicationsEriko Komiya
Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan; Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan
6 shared publicationsSatoshi Iwata
Division of Clinical Immunology, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
6 shared publications
Latest Publications
- Open Access
- 6 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 748
Functional Roles of CD26/DPP4 in Bleomycin-Induced Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary hypertension (PH) with interstitial lung diseases (ILDs) often causes intractable conditions. CD26/Dipeptidyl peptidase-4 (DPP4) is expressed in lung constituent cells and may be related to the pathogenesis of various respiratory diseases. We aimed to clarify the functional roles of CD26/DPP4 in PH-ILD, paying particular attention to vascular smooth muscle cells (SMCs). Dpp4 knockout (Dpp4KO) and wild type (WT) mice were administered bleomycin (BLM) intraperitoneally to establish a PH-ILD model. The BLM-induced increase in the right ventricular systolic pressure and the right ventricular hypertrophy observed in WT mice were attenuated in Dpp4KO mice. The BLM-induced vascular muscularization in small pulmonary vessels in Dpp4KO mice was milder than that in WT mice. The viability of TGFβ-stimulated human pulmonary artery SMCs (hPASMCs) was lowered due to the DPP4 knockdown with small interfering RNA. According to the results of the transcriptome analysis, upregulated genes in hPASMCs with TGFβ treatment were related to pulmonary vascular SMC proliferation via the Notch, PI3K-Akt, and NFκB signaling pathways. Additionally, DPP4 knockdown in hPASMCs inhibited the pathways upregulated by TGFβ treatment. These results suggest that genetic deficiency of Dpp4 protects against BLM-induced PH-ILD by alleviating vascular remodeling, potentially through the exertion of an antiproliferative effect via inhibition of the TGFβ-related pathways in PASMCs.
- 6 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 748
Open AccessFunctional Roles of CD26/DPP4 in Bleomycin-Induced Pulmonary Hypertension Associated with Interstitial Lung Disease
Pulmonary hypertension (PH) with interstitial lung diseases (ILDs) often causes intractable conditions. CD26/Dipeptidyl peptidase-4 (DPP4) is expressed in lung constituent cells and may be related to the pathogenesis of various respiratory diseases. We aimed to clarify the functional roles of CD26/DPP4 in PH-ILD, paying particular attention to vascular smooth muscle cells (SMCs). Dpp4 knockout (Dpp4KO) and wild type (WT) mice were administered bleomycin (BLM) intraperitoneally to establish a PH-ILD model. The BLM-induced increase in the right ventricular systolic pressure and the right ventricular hypertrophy observed in WT mice were attenuated in Dpp4KO mice. The BLM-induced vascular muscularization in small pulmonary vessels in Dpp4KO mice was milder than that in WT mice. The viability of TGFβ-stimulated human pulmonary artery SMCs (hPASMCs) was lowered due to the DPP4 knockdown with small interfering RNA. According to the results of the transcriptome analysis, upregulated genes in hPASMCs with TGFβ treatment were related to pulmonary vascular SMC proliferation via the Notch, PI3K-Akt, and NFκB signaling pathways. Additionally, DPP4 knockdown in hPASMCs inhibited the pathways upregulated by TGFβ treatment. These results suggest that genetic deficiency of Dpp4 protects against BLM-induced PH-ILD by alleviating vascular remodeling, potentially through the exertion of an antiproliferative effect via inhibition of the TGFβ-related pathways in PASMCs.
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A2236
Functional Roles for CD26/DPP4 in Mouse Bleomycin-induced Pulmonary Fibrosis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A2236
Functional Roles for CD26/DPP4 in Mouse Bleomycin-induced Pulmonary Fibrosis
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3766
Functional Roles for CD26/DPP4 in LPS-induced Lung Injury in Mice
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A3766
Functional Roles for CD26/DPP4 in LPS-induced Lung Injury in Mice
- Open Access
- 21 May 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (6) , 1-17
IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells
Triple-negative breast cancer (TNBC) has a poor prognosis compared to other breast cancer subtypes. Although epidermal growth factor receptor (EGFR) is overexpressed in TNBC, clinical trials with EGFR inhibitors including tyrosine kinase inhibitors (EGFR-TKI) in TNBC have heretofore been unsuccessful. To develop effective EGFR-targeted therapy for TNBC, the precise mechanisms of EGFR-TKI resistance in TNBC need to be elucidated. In this study, to understand the molecular mechanisms involved in the differences in EGFR-TKI efficacy on TNBC between human and mouse, we focused on the effect of IL-26, which is absent in mice. In vitro analysis showed that IL-26 activated AKT and JNK signaling of bypass pathway of EGFR-TKI in both murine and human TNBC cells. We next investigated the mechanisms involved in IL-26-mediated EGFR-TKI resistance in TNBC. We identified EphA3 as a novel functional receptor for IL-26 in TNBC. IL-26 induced dephosphorylation and downmodulation of EphA3 in TNBC, which resulted in increased phosphorylation of AKT and JNK against EGFR-TKI-induced endoplasmic reticulum (ER) stress, leading to tumor growth. Meanwhile, the blockade of IL-26 overcame EGFR-TKI resistance in TNBC. Since the gene encoding IL-26 is absent in mice, we utilized humanIL-26transgenic (hIL-26Tg) mice as a tumor-bearing murine model to characterize the role of IL-26 in the differential effect of EGFR-TKI in human and mice and to confirm our in vitro findings. Our findings indicate that IL-26 activates the bypass pathway of EGFR-TKI, while blockade of IL-26 overcomes EGFR-TKI resistance in TNBC via enhancement of ER stress signaling. Our work provides novel insights into the mechanisms of EGFR-TKI resistance in TNBC via interaction of IL-26 with its newly identified receptor EphA3, while also suggesting IL-26 as a possible therapeutic target in TNBC.
- 21 May 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (6) , 1-17
Open AccessIL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells
Triple-negative breast cancer (TNBC) has a poor prognosis compared to other breast cancer subtypes. Although epidermal growth factor receptor (EGFR) is overexpressed in TNBC, clinical trials with EGFR inhibitors including tyrosine kinase inhibitors (EGFR-TKI) in TNBC have heretofore been unsuccessful. To develop effective EGFR-targeted therapy for TNBC, the precise mechanisms of EGFR-TKI resistance in TNBC need to be elucidated. In this study, to understand the molecular mechanisms involved in the differences in EGFR-TKI efficacy on TNBC between human and mouse, we focused on the effect of IL-26, which is absent in mice. In vitro analysis showed that IL-26 activated AKT and JNK signaling of bypass pathway of EGFR-TKI in both murine and human TNBC cells. We next investigated the mechanisms involved in IL-26-mediated EGFR-TKI resistance in TNBC. We identified EphA3 as a novel functional receptor for IL-26 in TNBC. IL-26 induced dephosphorylation and downmodulation of EphA3 in TNBC, which resulted in increased phosphorylation of AKT and JNK against EGFR-TKI-induced endoplasmic reticulum (ER) stress, leading to tumor growth. Meanwhile, the blockade of IL-26 overcame EGFR-TKI resistance in TNBC. Since the gene encoding IL-26 is absent in mice, we utilized humanIL-26transgenic (hIL-26Tg) mice as a tumor-bearing murine model to characterize the role of IL-26 in the differential effect of EGFR-TKI in human and mice and to confirm our in vitro findings. Our findings indicate that IL-26 activates the bypass pathway of EGFR-TKI, while blockade of IL-26 overcomes EGFR-TKI resistance in TNBC via enhancement of ER stress signaling. Our work provides novel insights into the mechanisms of EGFR-TKI resistance in TNBC via interaction of IL-26 with its newly identified receptor EphA3, while also suggesting IL-26 as a possible therapeutic target in TNBC.
- Open Access
- 22 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
CD26/Dipeptidyl peptidase IV (DPPIV) is a cell surface glycoprotein with numerous roles including glucose metabolism, immunomodulation, and tumorigenesis. CD26/DPPIV is well recognized in diabetes, with DPPIV inhibitors being a class of oral hypoglycemic drugs called gliptins that are commonly used to treat type two diabetes mellitus. Recent work also indicated a potential role for CD26 in infectious diseases, including COVID-19, and immune-mediated disorders such as rheumatoid arthritis, inflammatory bowel disease, and graft-versus-host disease. In cancer, CD26/DPPIV expression has been characterized in numerous tumors such as hematologic malignancies, malignant pleural mesothelioma (MPM), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), and prostate, lung, colorectal, and ovarian (PLCO) cancer. Hence, CD26 has been frequently studied as a tumor biomarker and therapeutic target. CD26/DPPIV-targeted therapies have been evaluated in various cancers, including the use of anti-CD26 monoclonal antibodies as anticancer treatment in selected neoplasms. This review highlights our current understanding of the role of CD26 in cancer, diabetes, immune-mediated diseases, and infectious diseases. Enhanced understanding of CD26 biology and function may lead to novel therapeutic approaches in multiple human diseases.
- 22 February 2021
- Published by Springer Nature in Cureus
- Vol. 13 (2)
Open AccessCD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
CD26/Dipeptidyl peptidase IV (DPPIV) is a cell surface glycoprotein with numerous roles including glucose metabolism, immunomodulation, and tumorigenesis. CD26/DPPIV is well recognized in diabetes, with DPPIV inhibitors being a class of oral hypoglycemic drugs called gliptins that are commonly used to treat type two diabetes mellitus. Recent work also indicated a potential role for CD26 in infectious diseases, including COVID-19, and immune-mediated disorders such as rheumatoid arthritis, inflammatory bowel disease, and graft-versus-host disease. In cancer, CD26/DPPIV expression has been characterized in numerous tumors such as hematologic malignancies, malignant pleural mesothelioma (MPM), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastrointestinal stromal tumor (GIST), and prostate, lung, colorectal, and ovarian (PLCO) cancer. Hence, CD26 has been frequently studied as a tumor biomarker and therapeutic target. CD26/DPPIV-targeted therapies have been evaluated in various cancers, including the use of anti-CD26 monoclonal antibodies as anticancer treatment in selected neoplasms. This review highlights our current understanding of the role of CD26 in cancer, diabetes, immune-mediated diseases, and infectious diseases. Enhanced understanding of CD26 biology and function may lead to novel therapeutic approaches in multiple human diseases.
- 1 April 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (4) , 878-889
Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis
- 1 April 2019
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 139 (4) , 878-889
Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis
- 20 December 2018
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 29 (5) , 721-732
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy
Immune checkpoint inhibitors (ICIs) have drastically altered cancer treatment paradigms, with increasing numbers of novel ICIs being currently evaluated in numerous clinical trials for various cancers. ICIs release “brakes” against tumor immunity to control cancer growth via T cell-dependent anti-tumor activity. Meanwhile, side effects associated with ICIs are directly related to their mechanism of action, as nonspecific immune activation targeting non-tumor organs results in undesirable off-target inflammation and autoimmunity. Accumulating data reveal that immune-related adverse events (irAEs) of ICIs in cancer patients can resemble various rheumatic diseases. Moreover, while patients with preexisting rheumatic diseases can theoretically experience irAEs and disease flares, observational studies have shown that ICIs can be used successfully in these patients. As ICIs continue to provide long-lasting disease control in cancer patients and their usage correspondingly increases, the rheumatologist will be managing new ICI-associated clinical entities mimicking common autoimmune diseases and will need to be prepared to rapidly diagnose and treat these irAEs. Early recognition and treatment of these rheumatic adverse events will allow for improved outcomes and quality of life for cancer patients faced with previously rapidly fatal disease.
- 20 December 2018
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 29 (5) , 721-732
Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy
Immune checkpoint inhibitors (ICIs) have drastically altered cancer treatment paradigms, with increasing numbers of novel ICIs being currently evaluated in numerous clinical trials for various cancers. ICIs release “brakes” against tumor immunity to control cancer growth via T cell-dependent anti-tumor activity. Meanwhile, side effects associated with ICIs are directly related to their mechanism of action, as nonspecific immune activation targeting non-tumor organs results in undesirable off-target inflammation and autoimmunity. Accumulating data reveal that immune-related adverse events (irAEs) of ICIs in cancer patients can resemble various rheumatic diseases. Moreover, while patients with preexisting rheumatic diseases can theoretically experience irAEs and disease flares, observational studies have shown that ICIs can be used successfully in these patients. As ICIs continue to provide long-lasting disease control in cancer patients and their usage correspondingly increases, the rheumatologist will be managing new ICI-associated clinical entities mimicking common autoimmune diseases and will need to be prepared to rapidly diagnose and treat these irAEs. Early recognition and treatment of these rheumatic adverse events will allow for improved outcomes and quality of life for cancer patients faced with previously rapidly fatal disease.
- 1 October 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 504 (2) , 491-498
Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22
- 1 October 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 504 (2) , 491-498
Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22
- 1 January 2018
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 23 (9) , 1754-1779
A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target
CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV activity that is expressed on numerous cell types and has a multitude of biological functions. The role of CD26 in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell-T-cell interaction. In this paper, we will review emerging data on CD26-mediated immune regulation suggesting that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders as well as Middle East respiratory syndrome coronavirus. Moreover, we have had a long-standing interest in the role of CD26 in cancer biology and its suitability as a novel therapeutic target in selected neoplasms. We reported robust in vivo data on the anti-tumor activity of anti-CD26 monoclonal antibody in mouse xenograft models. We herein review significant novel findings and the early clinical development of a CD26-targeted therapy in selected immune disorders and cancers, advances that can lead to a more hopeful future for patients with these intractable diseases.
- 1 January 2018
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 23 (9) , 1754-1779
A novel nbsp role for CD26 dipeptidyl peptidase IV as a therapeutic target
CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV activity that is expressed on numerous cell types and has a multitude of biological functions. The role of CD26 in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell-T-cell interaction. In this paper, we will review emerging data on CD26-mediated immune regulation suggesting that CD26 may be an appropriate therapeutic target for the treatment of selected immune disorders as well as Middle East respiratory syndrome coronavirus. Moreover, we have had a long-standing interest in the role of CD26 in cancer biology and its suitability as a novel therapeutic target in selected neoplasms. We reported robust in vivo data on the anti-tumor activity of anti-CD26 monoclonal antibody in mouse xenograft models. We herein review significant novel findings and the early clinical development of a CD26-targeted therapy in selected immune disorders and cancers, advances that can lead to a more hopeful future for patients with these intractable diseases.
- 1 June 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 86 (3) , 212-221
A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus
- 1 June 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 86 (3) , 212-221
A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus